CEL-SCI Corporation

CEL-SCI Corporation a clinical-stage biotechnology company engages in the research development and manufacturing of immune systems for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine a Leukocyte Interleukin injection which has completed a pivotal Phase 3 clinical trial for patients who are diagnosed with locally advanced primary squamous cell carcinoma of the head and neck. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology a patented T-cell modulation process that stimulates the human immune system to fight bacterial viral parasitic infections autoimmune conditions allergies transplantation rejections and cancer. In addition the company is developing CEL-2000 and CEL-4000 which are LEAPS based product candidates for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna Virginia.